PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22450814-6	2012	These effects by saracatinib were not accompanied by the expected decline of Src family kinases but were accompanied by Akt-mammalian target of rapamycin suppression and/or mediated via another pathway.	saracatinib	17-28	mechanistic target of rapamycin kinase	Homo sapiens	124-153	
19451593-10	2009	AZD0530-resistant tumors showed activation of bypass pathways including MEK and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin, raising the possibility that MEK, mammalian target of rapamycin (mTOR), or PI3K inhibitors may augment Src inhibitor efficacy.	saracatinib	0-7	mechanistic target of rapamycin kinase	Homo sapiens	121-150	
20669046-7	2011	Proteomic analysis revealed striking bypass activation of the mTOR pathway in saracatinib-resistant tumors.	saracatinib	78-89	mechanistic target of rapamycin kinase	Homo sapiens	62-66	
20669046-10	2011	The use of mTOR kinase inhibitors with saracatinib may subvert drug resistance and prove to be more effective than saracatinib alone.	saracatinib	39-50	mechanistic target of rapamycin kinase	Homo sapiens	11-15	
20669046-10	2011	The use of mTOR kinase inhibitors with saracatinib may subvert drug resistance and prove to be more effective than saracatinib alone.	saracatinib	115-126	mechanistic target of rapamycin kinase	Homo sapiens	11-15	
19451593-10	2009	AZD0530-resistant tumors showed activation of bypass pathways including MEK and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin, raising the possibility that MEK, mammalian target of rapamycin (mTOR), or PI3K inhibitors may augment Src inhibitor efficacy.	saracatinib	0-7	mechanistic target of rapamycin kinase	Homo sapiens	186-215	
19451593-10	2009	AZD0530-resistant tumors showed activation of bypass pathways including MEK and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin, raising the possibility that MEK, mammalian target of rapamycin (mTOR), or PI3K inhibitors may augment Src inhibitor efficacy.	saracatinib	0-7	mechanistic target of rapamycin kinase	Homo sapiens	217-221